文献速递血栓与止血

免疫性血小板减少症患者接种SARS-CoV-2疫苗的真实世界单中心经验

Real-world, single-center experience of SARS-CoV-2 vaccination in immune thrombocytopenia.
PubMed 文献 · J Thromb Haemost · 2022-04-05

该单中心回顾性分析纳入294例活跃随访的免疫性血小板减少症(ITP)患者,接种SARS-CoV-2疫苗后ITP复发率为6.6%,新诊断ITP发生率为1.4%。接种后血小板计数较基线显著偏离(P≤.0001),17例中16例(94%)需治疗干预,随访结束时4例(24%)仍对治疗无反应且血小板计数<30×10^9/L。

要点

  • 294例ITP患者接种SARS-CoV-2疫苗后复发率6.6%,新诊断ITP发生率1.4%。
  • 接种后血小板计数较基线显著偏离(P≤.0001),17例中15例(88%)出现症状。
  • 17例中16例(94%)需治疗干预,随访结束时4例(24%)仍无反应且血小板<30×10^9/L。

核心结论

  • ITP患者接种SARS-CoV-2疫苗仍具有重要临床获益,但针对复发患者的推荐仍缺乏。
  • 本报告描述了SARS-CoV-2疫苗广泛接种时代的真实世界患者结局。

研究设计与样本

  • 单中心真实世界队列,回顾性审查294例活跃随访ITP患者的疫苗接种状态。
  • 识别17例接种SARS-CoV-2疫苗后ITP复发患者,复发率6.6%,新诊断ITP发生率1.4%。

主要发现

  • 接种后患者血小板计数较基线出现显著偏离(P≤.0001)。
  • 17例中14例既往诊断为ITP,诊断后中位随访4年(范围0-45年)。
  • 从接种到就诊间隔2-42天(中位14天),随访期34周。
  • 17例中15例(88%)就诊时有症状,全部17例在随访期内出现症状。
  • 随访期内9例(53%)接种第二剂疫苗,其中7例(78%)需治疗支持以完成第二剂接种。

关键数值与推荐

  • 治疗决策为多因素综合判断,目标为减轻出血症状并使血小板计数>30×10^9/L。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune thrombocytopenic purpura (ITP) relapse following vaccination remains poorly reported in the adult population. OBJECTIVES: This report details real world data from the largest single-center cohort of ITP relapse following severe acute respiratory syndrome (SARS-CoV-2) vaccination. METHODS: The vaccination status of 294 patients under active follow-up was reviewed. A total of 17 patients were identified resulting in an incidence of ITP relapse following SARS-CoV-2 vaccination in this cohort of 6.6% and an incidence of newly diagnosed ITP following SARS-CoV-2 vaccination of 1.4%. RESULTS: Patients were noted to develop marked deviation of platelet count from baseline following vaccination (P =< .0001). Fourteen patients had a prior diagnosis of ITP and median follow-up following diagnosis was 4 years (range 0-45 years). Days from vaccination to presentation ranged from 2-42 (median 14) and the follow-up period was 34 weeks. Fifteen patients (88%) presented with symptoms and all 17 patients developed symptoms during the follow-up period. Nine patients (53%) received a second dose of vaccine during the follow-up period with seven patients (78%) requiring therapeutic support to facilitate second vaccination. Decision to treat patients was multi-factorial and aimed at decreasing bleeding symptoms and obtaining a platelet count >30 × 109 /L. Sixteen patients (94%) required therapeutic intervention and at the end of the follow-up period, four patients (24%) remained unresponsive to treatment with a platelet count <30 × 109 /L. CONCLUSION: Vaccination of ITP patients continues to have important clinical benefit; however, recommendations for patients who relapse remain lacking. This report outlines the real-world patient outcomes in the era of widespread SARS-CoV-2 vaccination.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Woolley P, Tailor A, Shah R, et al. Real-world, single-center experience of SARS-CoV-2 vaccination in immune thrombocytopenia. J Thromb Haemost. 2022. PMID: 35313390. doi:10.1111/jth.15704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。